Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Stopped early · Phase 2
Conditions studied: Carcinoma, Hepatocellular
In brief
The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.
Key facts
- Study ID
- NCT03433703
- Run by
- Eisai Inc.
- People needed
- 8
- Starts
- 2018-04-26
- Expected to finish
- 2019-01-07
- Last updated by the study team
- 2019-12-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Liver Research Institute — Pasadena, California, United States
- University of Florida — Gainesville, Florida, United States
- University of Louisville — Louisville, Kentucky, United States
- Ochsner Clinic Foundation — New Orleans, Louisiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.